Newswire (Published: Thursday, March 19, 2020, Received: Thursday, March 19, 2020, 6:00:17 PM CDT)

Word Count: 335

2020 MAR 19 (NewsRx) -- By a News Reporter-Staff News Editor at Blood Daily News -- Current study results on Oncology - Prostate Cancer have been published. According to news reporting out of Omaha, Nebraska, by NewsRx editors, research stated, “The antiandrogen therapeutics apalutamide and darolutamide entered the clinic in 2018 and 2019, respectively, for the treatment of castration-resistant prostate cancer (CRPC). Increased expression of the enzyme aldo-keto reductase 1C3 (AKR1C3) is phenotypic of CRPC.”

Our news journalists obtained a quote from the research from the University of Nebraska Medical Center, “The enzyme acts to circumvent castration by producing potent androgens that drive proliferation. Furthermore, AKR1C3 mediates chemotherapeutic resistance to the standard of care, enzalutamide, a structural analogue of apalutamide. Resistance develops in almost all CRPC patients within three months of beginning treatment. Herein, we report that both apalutamide and the structurally distinct darolutamide induce AKR1C3 expression in models of prostate cancer and are susceptible to AKR1C3-mediated resistance.”

According to the news editors, the research concluded: “This effect is countered by pretreatment with a potent and highly selective AKR1C3 inhibitor, sensitizing high AKR1C3 expressing prostate cancer cell lines to the action of both chemotherapeutics with a concomitant reduction in expression of AKR1C3 and the biomarker prostate-specific antigen.”

For more information on this research see: Reversal of Apalutamide and Darolutamide Aldo-Keto Reductase 1C3-Mediated Resistance by a Small Molecule Inhibitor. Acs Chemical Biology, 2020;():. (American Chemical Society - www.acs.org; Acs Chemical Biology - http://www.pubs.acs.org/journal/acbcct)

Our news journalists report that additional information may be obtained by contacting P.C. Trippier, Dept. of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, Nebraska 68198, United States.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1021/acschembio.0c00069. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)

Companies

University of Nebraska Medical Center
American Chemical Society

Industries

Healthcare
      Healthcare Facilities
            Hospitals

Places

North America
United States
Americas
Nebraska
Omaha

Subjects

Science and Technology
      Scientific Research
            Medical Research
      Sciences
            Physical Sciences
                  Chemistry
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Health Sciences
            Medical Research
      Treatments and Therapies
            Medicinal Drugs